Fig. 1.

Relative risk of MACE as a function of baseline CV risk and distribution of subjects. Hazard ratio for treatment effect (semaglutide vs comparator) and 95% CI estimated using a stratified Cox proportional hazards model including effects of treatment, CV risk score and interaction between both. The x-axis shows the CV risk score derived from subjects’ baseline characteristics in the semaglutide trials. Data on graph cut off at the 5th and 95th percentile of the whole dataset. Hazard ratio value of 1.00 is indicated by a horizontal dashed line. Underlying histograms: distribution of subjects in the glycemic efficacy trials or CVOTs across baseline CV risk scores (histogram data for 439 subjects not shown, as these subjects had a CV risk score of < –3.0 or > 0.0). CI confidence interval, CV cardiovascular, CVOT cardiovascular outcomes trial, HR hazard ratio, MACE major adverse cardiovascular events